Sakar Healthcare Limited

NSEI:SAKAR Stock Report

Market Cap: ₹6.6b

Sakar Healthcare Past Earnings Performance

Past criteria checks 2/6

Sakar Healthcare has been growing earnings at an average annual rate of 6.5%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 14.5% per year. Sakar Healthcare's return on equity is 4.6%, and it has net margins of 7.5%.

Key information

6.5%

Earnings growth rate

-1.8%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate14.5%
Return on equity4.6%
Net Margin7.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Sakar Healthcare's (NSE:SAKAR) Anemic Earnings Might Be Worse Than You Think

Oct 30
Sakar Healthcare's (NSE:SAKAR) Anemic Earnings Might Be Worse Than You Think

Recent updates

Sakar Healthcare's (NSE:SAKAR) Anemic Earnings Might Be Worse Than You Think

Oct 30
Sakar Healthcare's (NSE:SAKAR) Anemic Earnings Might Be Worse Than You Think

Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Dec 28
Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Aug 05
Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Mar 29
Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Here's Why Sakar Healthcare (NSE:SAKAR) Has Caught The Eye Of Investors

Jan 31
Here's Why Sakar Healthcare (NSE:SAKAR) Has Caught The Eye Of Investors

Is Sakar Healthcare (NSE:SAKAR) Using Too Much Debt?

Dec 01
Is Sakar Healthcare (NSE:SAKAR) Using Too Much Debt?

Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

Jul 13
Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

Mar 26
Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

With EPS Growth And More, Sakar Healthcare (NSE:SAKAR) Is Interesting

Jul 01
With EPS Growth And More, Sakar Healthcare (NSE:SAKAR) Is Interesting

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Might Deserve Your Attention Today

Mar 23
Here's Why I Think Sakar Healthcare (NSE:SAKAR) Might Deserve Your Attention Today

Insider Buying: The Sakar Healthcare Limited (NSE:SAKAR) Chairman & MD Just Bought 7.1% More Shares

Mar 02
Insider Buying: The Sakar Healthcare Limited (NSE:SAKAR) Chairman & MD Just Bought 7.1% More Shares

Has Sakar Healthcare Limited's (NSE:SAKAR) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Feb 08
Has Sakar Healthcare Limited's (NSE:SAKAR) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Jan 10
Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Is An Interesting Stock

Dec 14
Here's Why I Think Sakar Healthcare (NSE:SAKAR) Is An Interesting Stock

Should You Rely On Sakar Healthcare's (NSE:SAKAR) Earnings Growth?

Nov 22
Should You Rely On Sakar Healthcare's (NSE:SAKAR) Earnings Growth?

Revenue & Expenses Breakdown

How Sakar Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NSEI:SAKAR Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,6501242060
30 Jun 241,5551121980
31 Mar 241,5421171990
31 Dec 231,5181252010
30 Sep 231,4801442030
30 Jun 231,4381271890
31 Mar 231,3421281690
31 Dec 221,3021781690
30 Sep 221,2651391550
30 Jun 221,2651441520
31 Mar 221,2911521540
31 Dec 211,139801310
30 Sep 211,109971330
30 Jun 211,0541181340
31 Mar 219531071330
31 Dec 209131181370
30 Sep 208701221320
30 Jun 208841061300
31 Mar 20839961230
31 Dec 19851881140
30 Sep 19844861120
30 Jun 1974478980
31 Mar 1968867910
31 Mar 1853438690
31 Mar 1744734600
31 Mar 1641422500
31 Dec 1538624490
31 Mar 1535018400
31 Mar 1429718330

Quality Earnings: SAKAR has high quality earnings.

Growing Profit Margin: SAKAR's current net profit margins (7.5%) are lower than last year (9.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SAKAR's earnings have grown by 6.5% per year over the past 5 years.

Accelerating Growth: SAKAR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SAKAR had negative earnings growth (-13.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.4%).


Return on Equity

High ROE: SAKAR's Return on Equity (4.6%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 09:55
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sakar Healthcare Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution